— Know what they know.
Not Investment Advice

MEDP NASDAQ

Medpace Holdings, Inc.
1W: +9.2% 1M: +9.3% 3M: +18.5% YTD: +18.5% 1Y: +13.4% 3Y: +194.8% 5Y: +264.2%
$673.79
-2.98 (-0.44%)
After Hours: $672.75 (-1.04, -0.15%)
Weekly Expected Move ±5.1%
$601 $635 $669 $703 $738
NASDAQ · Healthcare · Medical - Diagnostics & Research · Tech Score Strong Buy · Power 76 · $18.9B mcap · 23M float · 1.34% daily turnover · Short 61% of daily vol
Credit Risk of going bust: lower than 87% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.51 (down 99.9%), Medpace Holdings, Inc. would be worth roughly what it owes.
Total debt $146.0M against a stock market value of $18.93B.
Distance to default 12.17 (Merton model): prices to 2026-10-26, balance sheet 2026-09-30, debt counted $73.0M (short-term plus half of long-term), stock volatility 45.4%; Altman Z'' 0.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Bullish 75
Insider—
Congress5 trades
ETF Holdings—
Key Statistics
Market Cap$18.9B
52W Range373-684.52
Volume305,671
Avg Volume303,368
Beta1.18
Dividend—
Analyst Ratings
4 Buy 15 Hold 0 Sell
Consensus Hold
Company Info
CEOAugust James Troendle
Employees6,500
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2016-08-11
5375 Medpace Way
Cincinnati, OH 45227
US
513 579 9911
About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Recent Insider Trades

NameTypeSharesPriceDate
BURWIG SUSAN E M-Exempt 2,700 $166.73 2026-10-21
BURWIG SUSAN E M-Exempt 2,700 $166.73 2026-10-21
BURWIG SUSAN E M-Exempt 3,000 $166.73 2026-10-12
BURWIG SUSAN E M-Exempt 3,000 $166.73 2026-10-12
BURWIG SUSAN E M-Exempt 2,000 $166.73 2026-10-07

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms